StocksFundsScreenerSectorsWatchlists
APYX

APYX - Apyx Medical Corp Stock Price, Fair Value and News

1.41USD+0.13 (+10.16%)Market Closed

Market Summary

APYX
USD1.41+0.13
Market Closed
10.16%

APYX Stock Price

View Fullscreen

APYX RSI Chart

APYX Valuation

Market Cap

43.3M

Price/Earnings (Trailing)

-2.31

Price/Sales (Trailing)

0.83

EV/EBITDA

-0.48

Price/Free Cashflow

-7.55

APYX Price/Sales (Trailing)

APYX Profitability

EBT Margin

-40.65%

Return on Equity

-69.51%

Return on Assets

-23.62%

Free Cashflow Yield

-13.24%

APYX Fundamentals

APYX Revenue

Revenue (TTM)

52.3M

Rev. Growth (Yr)

16.26%

Rev. Growth (Qtr)

22.43%

APYX Earnings

Earnings (TTM)

-18.7M

Earnings Growth (Yr)

-58.82%

Earnings Growth (Qtr)

-107.54%

Breaking Down APYX Revenue

Last 7 days

-30.2%

Last 30 days

-46.1%

Last 90 days

-50.6%

Trailing 12 Months

-38.1%

How does APYX drawdown profile look like?

APYX Financial Health

Current Ratio

5.52

Debt/Equity

0.33

Debt/Cashflow

-0.58

APYX Investor Care

Shares Dilution (1Y)

0.13%

Diluted EPS (TTM)

-0.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202344.2M47.4M50.3M52.3M
202252.4M51.4M48.7M44.5M
202131.4M38.3M43.2M48.5M
202027.6M25.3M24.6M27.7M
201918.8M21.8M25.7M28.2M
201812.0M13.4M14.4M16.6M
201730.5M23.5M16.1M10.2M
201631.2M33.2M35.4M36.6M
201527.3M27.7M28.7M29.5M
20148.0M14.4M20.8M27.7M
201326.6M25.2M13.4M1.6M
201226.0M26.6M27.0M27.7M
201124.8M25.7M25.5M25.4M
2010026.0M25.1M24.2M
200900027.0M

Tracking the Latest Insider Buys and Sells of Apyx Medical Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 12, 2023
hill matthew c
bought
5,475
2.19
2,500
chief financial officer
Nov 14, 2023
goodwin charles d. ii
bought
78,500
1.57
50,000
chief executive officer
Jul 12, 2023
waldman lawrence
acquired
15,853
2.97
5,338
-
Jun 26, 2023
hornsby todd
acquired
26,550
1.77
15,000
executive vice president
Jun 26, 2023
hornsby todd
sold
-113,400
7.56
-15,000
executive vice president
Jun 06, 2023
geraghty michael
acquired
27,900
2.79
10,000
-
Aug 29, 2022
goodwin charles d. ii
bought
70,067
5.96319
11,750
chief executive officer
Jul 11, 2022
citronowicz moshe
acquired
76,200
2.54
30,000
sr. v.p. of operations

1–10 of 27

Which funds bought or sold APYX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
added
0.07
-855,806
3,879,920
-%
Mar 05, 2024
GREENWOOD CAPITAL ASSOCIATES LLC
added
93.78
566,513
1,532,300
0.10%
Feb 15, 2024
BARCLAYS PLC
sold off
-100
-46,000
-
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
73,491
73,491
-%
Feb 15, 2024
HORIZON KINETICS ASSET MANAGEMENT LLC
unchanged
-
-356,700
1,611,300
0.03%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
new
-
33,531
33,531
-%
Feb 14, 2024
RTW INVESTMENTS, LP
reduced
-42.27
-2,999,000
2,688,020
0.04%
Feb 14, 2024
Cubist Systematic Strategies, LLC
sold off
-100
-54,803
-
-%
Feb 14, 2024
Squarepoint Ops LLC
added
60.2
78,047
328,485
-%
Feb 14, 2024
Caption Management, LLC
added
30.79
5,428
82,087
-%

1–10 of 47

Are Funds Buying or Selling APYX?

Are funds buying APYX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own APYX
No. of Funds

Unveiling Apyx Medical Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 25, 2024
hirschman orin
0%
0
SC 13G/A
Feb 14, 2024
divisadero street capital management, lp
0.0%
0
SC 13G/A
Feb 14, 2024
pura vida investments, llc
0.23%
80,000
SC 13G/A
Feb 14, 2024
rtw investments, lp
3.0%
1,025,963
SC 13G/A
Feb 13, 2024
archon capital management llc
9.96%
3,452,030
SC 13G/A
Feb 07, 2024
hirschman orin
5.9%
2,040,540
SC 13G/A
Feb 02, 2024
cowen financial products llc
-
0
SC 13G/A
Jan 23, 2024
royce & associates lp
6.23%
2,158,900
SC 13G
Jan 23, 2024
royce & associates lp
6.23%
2,158,900
SC 13G/A
Aug 14, 2023
hirschman orin
5.4%
1,884,281
SC 13G

Recent SEC filings of Apyx Medical Corp

View All Filings
Date Filed Form Type Document
Mar 25, 2024
SC 13G/A
Major Ownership Report
Mar 21, 2024
10-K
Annual Report
Mar 21, 2024
8-K
Current Report
Feb 21, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 07, 2024
SC 13G/A
Major Ownership Report
Feb 02, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Apyx Medical Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
196.9B
40.1B
-3.02% 19.11%
34.4
4.91
-8.12% -17.45%
71.2B
19.5B
2.28% 4.53%
56.69
3.65
4.02% -22.04%
24.6B
3.9B
3.45% 0.50%
55.33
6.38
3.42% 23.09%
21.7B
14.8B
1.75% 11.60%
8.16
1.46
2.12% 209.17%
MID-CAP
10.2B
2.7B
2.92% -30.26%
-16.04
3.83
-4.68% 82.43%
9.7B
12.3B
-3.34% -3.19%
23.21
0.78
-2.44% -22.68%
9.5B
3.5B
2.97% 25.27%
33.57
2.74
4.97% 18.89%
6.9B
4.0B
-2.47% -11.08%
-51.36
1.74
1.10% 85.84%
3.5B
366.4M
0.74% 28.92%
-577.22
9.59
33.86% 89.80%
2.5B
6.6B
-3.84% 3.03%
12.86
0.38
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
47.53% -25.51%
-2.23
0.47
7.73% -1066.14%
379.3M
166.7M
5.16% -2.53%
-4.59
2.28
6.67% -456.34%
227.2M
329.5M
-13.41% -54.45%
-16.09
0.69
0.49% 64.22%
43.3M
52.3M
-46.12% -38.06%
-2.31
0.83
17.61% 19.28%
4.5M
3.7M
2.40% 338.46%
-0.37
1.19
5.77% 8.23%

Apyx Medical Corp News

Latest updates
Simply Wall St • 30 hours ago
InvestorsObserver • 25 Mar 2024 • 04:46 pm
InvestorsObserver • 22 Mar 2024 • 10:57 am
Simply Wall St • 22 Mar 2024 • 10:53 am
Defense World • 14 Mar 2024 • 07:00 am
CNN • 22 Feb 2024 • 06:54 pm

Apyx Medical Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue22.4%14,662,00011,976,00013,569,00012,142,00012,611,0009,114,00010,292,00012,493,00016,824,00011,831,00011,224,0008,638,00011,464,0006,954,0004,296,0004,997,0008,382,0007,575,0006,649,0005,629,0005,845,000
Gross Profit11.9%8,929,0007,978,0009,279,0007,573,0008,241,0005,757,0006,914,0008,219,00012,151,0008,056,0007,534,0005,860,0007,701,0004,725,0002,094,0002,984,0005,563,0005,294,0004,674,0003,563,0003,556,000
Operating Expenses16.6%14,705,00012,615,00013,206,00013,184,00014,174,00011,539,00012,890,00014,090,00013,843,00012,024,00011,577,00010,605,0009,754,0009,096,0008,261,00010,476,00011,524,00010,050,0009,096,0009,293,0009,391,000
  S&GA Expenses38.9%6,724,0004,841,0005,378,0005,255,0005,809,0004,671,0004,539,0005,465,0006,021,0004,611,0004,261,0003,724,0002,996,0002,706,0002,189,0003,796,0003,870,0003,836,0003,037,0002,957,0003,186,000
  R&D Expenses-2.2%1,248,0001,276,0001,199,0001,121,0001,255,0001,061,0001,070,0001,158,000947,0001,175,0001,084,0001,115,000918,0001,047,000975,000980,0001,097,0001,016,000888,000730,000610,000
EBITDA Margin-11.9%-0.35-0.31-0.36-0.49-0.49-0.37-0.32-0.29-0.29-0.32-0.37-0.52-0.67--------
Interest Expenses90.8%1,116,000585,000543,000234,0003,0001,0003,0008,0001,0003,0002,0004,0007,00025,0008,0006,0008,000----1,000
Income Taxes127.4%87,000-318,00066,000-2,267,000151,00050,00096,00070,000134,00073,000107,00066,000-391,000-715,000-1,492,000-4,905,000-383,000171,00076,0006,000-1,523,000
Earnings Before Taxes-91.0%-9,537,000-4,993,000-953,000-5,799,000-5,914,000-5,745,000-5,354,000-5,898,000-1,876,000-4,161,000-3,944,000-4,839,000-1,922,000-4,449,000-6,182,000-6,856,000-5,816,000-4,199,000-4,219,000-5,602,000-5,435,000
EBT Margin-15.8%-0.41-0.35-0.39-0.52-0.51-0.39-0.34-0.30-0.31-0.34-0.40-0.55-0.70--------
Net Income-107.5%-9,607,000-4,629,000-994,000-3,483,000-6,049,000-5,764,000-5,426,000-5,945,000-2,003,000-4,222,000-4,046,000-4,901,000-1,527,000-3,728,000-4,690,000-1,951,000-5,433,000-4,370,000-4,295,000-5,608,000-3,912,000
Net Income Margin-18.6%-0.36-0.30-0.34-0.47-0.52-0.39-0.34-0.31-0.31-0.34-0.37-0.47-0.43--------
Free Cashflow-164.7%-2,256,0003,489,000-4,975,000-1,991,000-4,692,000-5,548,000-6,273,000-4,797,000-118,000-3,775,000-5,035,000-2,244,000-1,405,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets33.3%79.0059.0062.0057.0052.0055.0059.0063.0069.0068.0070.0071.0074.0075.0078.0082.0085.0087.0089.0092.0096.00
  Current Assets40.3%70.0050.0053.0053.0043.0046.0051.0055.0061.0060.0062.0063.0066.0068.0070.0074.0077.0079.0082.0085.0090.00
    Cash Equivalents97.5%44.0022.0019.0016.0010.0015.0020.0026.0031.0031.0035.0040.0042.0044.0046.0051.0059.0062.0067.0032.0017.00
  Inventory-12.1%10.0011.0011.0011.0012.0012.0010.007.007.006.005.004.004.005.005.006.005.007.006.006.005.00
  Net PPE-8.5%2.002.002.002.007.007.007.007.007.006.006.007.007.006.006.007.007.007.006.006.006.00
  Goodwill---------------------0.00
Liabilities102.3%52.0026.0026.0021.0014.0013.0013.0013.0015.0013.0012.0011.0010.0011.0011.0012.0013.0010.008.009.009.00
  Current Liabilities23.8%13.0010.0019.0019.0012.0011.0011.0012.0013.0012.0011.0010.009.0010.0010.0011.0012.009.008.009.009.00
  Long Term Debt-100.0%-9.00-------------------
    LT Debt, Current---9.009.00-----------------
    LT Debt, Non Current268.4%33.009.00-------------------
Shareholder's Equity-19.3%27.0033.0037.0036.0038.0042.0046.0050.0054.0055.0058.0060.0064.0064.0067.0070.0071.0076.0079.0083.0087.00
  Retained Earnings-21.4%-54.45-44.84-40.21-39.22-35.73-29.69-23.92-18.50-12.55-10.55-6.33-2.283.004.008.0013.0015.0020.0024.0029.0034.00
  Additional Paid-In Capital3.8%81.0078.0077.0075.0073.0072.0070.0068.0066.0065.0064.0062.0061.0060.0059.0058.0057.0056.0055.0054.0053.00
Accumulated Depreciation----3.005.005.005.005.005.005.005.005.005.005.005.005.004.00----
Shares Outstanding0.0%35.0035.0035.0035.0035.0035.0034.0034.0034.0034.0034.0034.00---------
Minority Interest-7.1%0.000.000.000.000.000.000.000.000.000.000.000.000.000.00-------
Float-------202---354---190---227--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-159.0%-2,1633,663-4,819-1,881-4,550-5,360-5,872-4,518214-3,605-5,006-2,052-1,017-2,616-5,026-7,407-3,251-4,549-5,586-5,089-18,046
  Share Based Compensation-32.3%9141,3511,4821,3671,6411,6921,7141,6501,3411,1841,3691,1941,0011,0631,0971,0499875438561,195986
Cashflow From Investing46.6%-93.00-1747,111-110-142-188-401-279-332-170-29.00-192-388-9.00-94.00-90.00-225-55840,48320,841-6,158
Cashflow From Financing14439.0%23,84416446.008,112-10.001272.0098.00-39.00-33.00157-61.00-134109-63.0015.00-5.0037.0048.0067.00137

APYX Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]  
Sales$ 52,349$ 44,510
Cost of sales18,59015,379
Gross profit33,75929,131
Other costs and expenses:  
Research and development4,8444,544
Professional services7,0319,044
Salaries and related costs19,63718,621
Selling, general and administrative22,19820,484
Total other costs and expenses53,71052,693
Gain on sale-leaseback2,6920
Loss from operations(17,259)(23,562)
Interest income921157
Interest expense(2,478)(15)
Other income, net622509
Loss on extinguishment of debt(3,088)0
Total other (loss) income, net(4,023)651
Loss from operations before income taxes(21,282)(22,911)
Income tax (benefit) expense(2,432)367
Net loss(18,850)(23,278)
Net loss attributable to non-controlling interest(137)(94)
Net loss attributable to stockholders$ (18,713)$ (23,184)
Loss per share - basic (in dollars per share)$ (0.54)$ (0.67)
Loss per share - diluted (in dollars per share)$ (0.54)$ (0.67)
Weighted average number of shares outstanding - basic (in shares)34,62234,516
Weighted average number of shares outstanding - dilutive (in shares)34,62234,516

APYX Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 43,652$ 10,192
Trade accounts receivable, net of allowance of $608 and $66814,02310,602
Income tax receivables07,545
Other receivables3099
Inventories, net of provision for obsolescence of $875 and $4579,92311,797
Prepaid expenses and other current assets2,7342,737
Total current assets70,36242,972
Property and equipment, net1,9156,761
Operating lease right-of-use assets5,162710
Finance lease right-of-use assets69115
Other assets1,7321,217
Total assets79,24051,775
Current liabilities:  
Accounts payable2,7122,669
Accrued expenses and other current liabilities9,6618,928
Current portion of operating lease liabilities347216
Current portion of finance lease liabilities2037
Total current liabilities12,74011,850
Long-term debt, net of debt discounts and issuance costs33,1850
Long-term operating lease liabilities4,896470
Long-term finance lease liabilities5373
Long-term contract liabilities1,2461,408
Other liabilities198181
Total liabilities52,31813,982
Commitments and Contingencies (Note 17)
EQUITY  
Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of December 31, 2023 and 202200
Common stock, $0.001 par value; 75,000,000 shares authorized; 34,643,888 issued and outstanding as of December 31, 2023, and 34,597,822 issued and outstanding as of December 31, 20223535
Additional paid-in capital81,11473,282
Accumulated deficit(54,448)(35,735)
Total stockholders' equity26,70137,582
Non-controlling interest221211
Total equity26,92237,793
Total liabilities and equity$ 79,240$ 51,775
APYX
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and laparoscopic surgical procedures. The company's Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also offers hand pieces for open and laparoscopic procedures, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
 CEO
 WEBSITEwww.apyxmedical.com
 EMPLOYEES276

Apyx Medical Corp Frequently Asked Questions


What is the ticker symbol for Apyx Medical Corp? What does APYX stand for in stocks?

APYX is the stock ticker symbol of Apyx Medical Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Apyx Medical Corp (APYX)?

As of Wed Mar 27 2024, market cap of Apyx Medical Corp is 43.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APYX stock?

You can check APYX's fair value in chart for subscribers.

What is the fair value of APYX stock?

You can check APYX's fair value in chart for subscribers. The fair value of Apyx Medical Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Apyx Medical Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APYX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Apyx Medical Corp a good stock to buy?

The fair value guage provides a quick view whether APYX is over valued or under valued. Whether Apyx Medical Corp is cheap or expensive depends on the assumptions which impact Apyx Medical Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APYX.

What is Apyx Medical Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, APYX's PE ratio (Price to Earnings) is -2.31 and Price to Sales (PS) ratio is 0.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APYX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Apyx Medical Corp's stock?

In the past 10 years, Apyx Medical Corp has provided -0.101 (multiply by 100 for percentage) rate of return.